Trial Profile
Phase II single-arm study of ON 01910.Na BY 4 HOUR INFUSION in patients with recurring platinum-resistant ovarian cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Sep 2016
Price :
$35
*
At a glance
- Drugs Rigosertib (Primary)
- Indications Ovarian cancer
- Focus Therapeutic Use
- 11 Apr 2012 Status changed from not yet recruiting to suspended as reported by Clinical Trials Registry - India.
- 20 Sep 2010 New trial record